About Us
Our Science
Corporate Governance
Investors
Media
Contact

About Us
Our Science
Corporate Governance
Investors
Media
Contact

Financial calendar

Upcoming events

2020
2019
All years

Financial

All events
Events

December 9, 2020

Interim Report May – October 2020

Read more

Investor contact

Cord Communications

IR@oasmia.com

+46 18-50 54 40

Subscribe to our news

Investors

About Us
Our Science
Corporate Governance
Investors
Media
Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com

We uses cookies in order to optimize your use of our website. Read more about cookies.

No, I do not accept cookies Yes, I accept cookies